The YSI 2900 series biochemistry analyser has been increasingly used in understanding the growth and survival of cancer cells.
During April, the Molecular Cancer Therapeutics journal published a paper which showed the results of experiments carried out using CB-839 for antitumour activity monitoring in Triple-Negative breast cancer.
In this research, media concentrations of glucose, lactate, glutamine and glutamate in tissue culture media were quantified using the YSI 2900 Biochemistry Analyser.
Cells were incubated in DMEM with 5 mmol/L glucose and 0.5 mmol/L glutamine (no serum) for six hours.
The research demonstrated that Triple-Negative breast cancer cells are particularly dependent on glutamine for growth and survival, and that the activity of the glutaminase can be inhibited with CB-839.
The YSI 2900 Series is a popular choice for bioprocessing research work as it gives accurate results in less than one minute and combines the well-established YSI sensor technology with up to the minute features, such as anti-clogging mechanisms, flexible connectivity, 96 well plate sampling, and now with the latest 2900M Monitoring & Control model, automatic online asceptic sampling.
For more information, please visit: www.ysilifesciences.com
